Antiviral drugs and vaccines currently used for COVID-19
The beginning of the 21st century was marked by the emergence of the SARS-CoV-2 virus, which is the infectious cause of COVID-19 disease. The disorder is characterized by various courses and symptoms mostly arising from the upper and lower respiratory tract. Within a short period of time, the SARS-C...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Polish |
| Published: |
Polish Pharmaceutical Society
2023-12-01
|
| Series: | Farmacja Polska |
| Subjects: | |
| Online Access: | https://www.ptfarm.pl/download/?file=File%2FFarmacja+Polska%2F2023%2F9%2F01_OG_Leki_szczepionki_COVID_19_n.pdf |
| _version_ | 1827396681767845888 |
|---|---|
| author | Łukasz Dobrek |
| author_facet | Łukasz Dobrek |
| author_sort | Łukasz Dobrek |
| collection | DOAJ |
| description | The beginning of the 21st century was marked by the emergence of the SARS-CoV-2 virus, which is the infectious cause of COVID-19 disease. The disorder is characterized by various courses and symptoms mostly arising from the upper and lower respiratory tract. Within a short period of time, the SARS-CoV-2 infection became a global pandemic and caused widespread global health, social and economic consequences. Due to the initial lack of possibility of causal treatment of the infection and specific methods of primary prevention, and in the face of the emergence of subsequent genetic variants of SARS-CoV-2, extensive and comprehensive research was undertaken to introduce new drugs with anti-coronavirus activity and novel vaccines enabling active immunization against COVID-19. The research resulted in the relatively quick registration of the first mRNA-based vaccines and vector vaccines as well as intruducing symptomatic treatment regimens for SARS-CoV-2 infection. The increasing knowledge regarding the COVID-19 pathophysiology allowed to identify new, potential target side of action of new compounds applicable in the treatment of COVID-19. They include agents with immunomodulatory effects (reducing the risk of a "cytokine storm" during infection), inhibitors of intracellular entry of SARS-CoV-2 (compounds against the superficial viral spike protein) or inhibitors of intracellular viral replication (nucleoside analogues, protease inhibitors). The aim of the study was to synthetically provide the up-to-date state of knowledge regarding currently used vaccines and specific antiviral treatment of COVID-19. The manuscript is a narrative review describing the pathophysiology of SARS-CoV-2 infection and COVID-19 symptomatology and briefly characterizing both the vaccines against COVID-19 currently registered by the European Medicines Agency (EMA) and/or the US Food and Drug Administration (FDA) (company products: BioNTech and Pfizer, Moderna Biotech Spain S.L., Janssen-Cilag International NV, Novavax CZ, a.s., AstraZeneca AB, Sanofi Pasteur, Valneva Austria GmbH and HIPRA Human Health S.L.U.). Moreover, antiviral drugs against SARS-CoV-2 infection (Tixagevimab / Cilgavimab, Anakinra, Nirmatrelvir / Ritonavir, Regdanvimab, Casirivimab / Imdevimab, Remdesivir, Sotrovimab, Tocilizumab, Baricitinib, Molnupiravir, Vilobelimab) were described. |
| first_indexed | 2024-03-08T18:55:41Z |
| format | Article |
| id | doaj.art-378c8ac809f04e0ea3c5a86bf2d7749c |
| institution | Directory Open Access Journal |
| issn | 0014-8261 |
| language | Polish |
| last_indexed | 2024-03-08T18:55:41Z |
| publishDate | 2023-12-01 |
| publisher | Polish Pharmaceutical Society |
| record_format | Article |
| series | Farmacja Polska |
| spelling | doaj.art-378c8ac809f04e0ea3c5a86bf2d7749c2023-12-28T13:32:11ZpolPolish Pharmaceutical SocietyFarmacja Polska0014-82612023-12-0179950752710.32383/farmpol/176517176517Antiviral drugs and vaccines currently used for COVID-19Łukasz Dobrek0https://orcid.org/0000-0001-5049-0026Katedra i Zakład Farmakologii Klinicznej, Uniwersytet Medyczny im. Piastów Śląskich we Wrocławiu, PolskaThe beginning of the 21st century was marked by the emergence of the SARS-CoV-2 virus, which is the infectious cause of COVID-19 disease. The disorder is characterized by various courses and symptoms mostly arising from the upper and lower respiratory tract. Within a short period of time, the SARS-CoV-2 infection became a global pandemic and caused widespread global health, social and economic consequences. Due to the initial lack of possibility of causal treatment of the infection and specific methods of primary prevention, and in the face of the emergence of subsequent genetic variants of SARS-CoV-2, extensive and comprehensive research was undertaken to introduce new drugs with anti-coronavirus activity and novel vaccines enabling active immunization against COVID-19. The research resulted in the relatively quick registration of the first mRNA-based vaccines and vector vaccines as well as intruducing symptomatic treatment regimens for SARS-CoV-2 infection. The increasing knowledge regarding the COVID-19 pathophysiology allowed to identify new, potential target side of action of new compounds applicable in the treatment of COVID-19. They include agents with immunomodulatory effects (reducing the risk of a "cytokine storm" during infection), inhibitors of intracellular entry of SARS-CoV-2 (compounds against the superficial viral spike protein) or inhibitors of intracellular viral replication (nucleoside analogues, protease inhibitors). The aim of the study was to synthetically provide the up-to-date state of knowledge regarding currently used vaccines and specific antiviral treatment of COVID-19. The manuscript is a narrative review describing the pathophysiology of SARS-CoV-2 infection and COVID-19 symptomatology and briefly characterizing both the vaccines against COVID-19 currently registered by the European Medicines Agency (EMA) and/or the US Food and Drug Administration (FDA) (company products: BioNTech and Pfizer, Moderna Biotech Spain S.L., Janssen-Cilag International NV, Novavax CZ, a.s., AstraZeneca AB, Sanofi Pasteur, Valneva Austria GmbH and HIPRA Human Health S.L.U.). Moreover, antiviral drugs against SARS-CoV-2 infection (Tixagevimab / Cilgavimab, Anakinra, Nirmatrelvir / Ritonavir, Regdanvimab, Casirivimab / Imdevimab, Remdesivir, Sotrovimab, Tocilizumab, Baricitinib, Molnupiravir, Vilobelimab) were described.https://www.ptfarm.pl/download/?file=File%2FFarmacja+Polska%2F2023%2F9%2F01_OG_Leki_szczepionki_COVID_19_n.pdftreatmentvaccinecovid-19sars-cov-2antiviral drug |
| spellingShingle | Łukasz Dobrek Antiviral drugs and vaccines currently used for COVID-19 Farmacja Polska treatment vaccine covid-19 sars-cov-2 antiviral drug |
| title | Antiviral drugs and vaccines currently used for COVID-19 |
| title_full | Antiviral drugs and vaccines currently used for COVID-19 |
| title_fullStr | Antiviral drugs and vaccines currently used for COVID-19 |
| title_full_unstemmed | Antiviral drugs and vaccines currently used for COVID-19 |
| title_short | Antiviral drugs and vaccines currently used for COVID-19 |
| title_sort | antiviral drugs and vaccines currently used for covid 19 |
| topic | treatment vaccine covid-19 sars-cov-2 antiviral drug |
| url | https://www.ptfarm.pl/download/?file=File%2FFarmacja+Polska%2F2023%2F9%2F01_OG_Leki_szczepionki_COVID_19_n.pdf |
| work_keys_str_mv | AT łukaszdobrek antiviraldrugsandvaccinescurrentlyusedforcovid19 |